These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 25880488)
1. Decision aids for benign prostatic hyperplasia and prostate cancer. Arterburn D; Wellman R; Westbrook EO; Ross TR; McCulloch D; Handley M; Lowe M; Cable C; Zeliadt SB; Hoffman RM Am J Manag Care; 2015 Feb; 21(2):e130-40. PubMed ID: 25880488 [TBL] [Abstract][Full Text] [Related]
2. Men's theories about benign prostatic hyperplasia and prostate cancer following a benign prostatic hyperplasia decision aid. Holmes-Rovner M; Price C; Rovner DR; Kelly-Blake K; Lillie J; Wills C; Bonham VL J Gen Intern Med; 2006 Jan; 21(1):56-60. PubMed ID: 16423124 [TBL] [Abstract][Full Text] [Related]
3. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL Br J Cancer; 2003 Mar; 88(6):928-32. PubMed ID: 12644831 [TBL] [Abstract][Full Text] [Related]
4. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study]. Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070 [TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL Saudi Med J; 2004 Apr; 25(4):447-51. PubMed ID: 15083213 [TBL] [Abstract][Full Text] [Related]
6. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214 [TBL] [Abstract][Full Text] [Related]
8. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Tayeb MT; Clark C; Sharp L; Haites NE; Rooney PH; Murray GI; Payne SN; McLeod HL Oncol Rep; 2002; 9(3):653-5. PubMed ID: 11956645 [TBL] [Abstract][Full Text] [Related]
9. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. Plosker GL; Goa KL Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827 [TBL] [Abstract][Full Text] [Related]
10. Whole-genome gene expression analysis in urine samples of patients with prostate cancer and benign prostate hyperplasia. Özdemir TR; Şimşir A; Onay H; Cüreklibatır İ; Özkınay F; Akın H Urol Oncol; 2017 Oct; 35(10):607.e15-607.e24. PubMed ID: 28647394 [TBL] [Abstract][Full Text] [Related]
11. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. DiSantostefano RL; Biddle AK; Lavelle JP BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339 [TBL] [Abstract][Full Text] [Related]
12. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG; J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Ackerman SJ; Rein AL; Blute M; Beusterien K; Sullivan EM; Tanio CP; Manyak MJ; Strauss MJ Urology; 2000 Dec; 56(6):972-80. PubMed ID: 11113743 [TBL] [Abstract][Full Text] [Related]
14. Glutathione S-transferase gene variants and risk of benign prostate hyperplasia in a North Indian population. Konwar R; Manchanda PK; Chaudhary P; Nayak VL; Singh V; Bid HK Asian Pac J Cancer Prev; 2010; 11(2):365-70. PubMed ID: 20843117 [TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results. Blute M; Ackerman SJ; Rein AL; Beusterien K; Sullivan EM; Tanio CP; Strauss MJ; Manyak MJ Urology; 2000 Dec; 56(6):981-7. PubMed ID: 11113744 [TBL] [Abstract][Full Text] [Related]
16. The agreement among urological experts on the diagnostic management of patients with common urological problems. Hansen MV; Zdanowski A Br J Urol; 1997 Nov; 80(5):787-92. PubMed ID: 9393304 [TBL] [Abstract][Full Text] [Related]
17. Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia. Tayeb MT; Clark C; Murray GI; Sharp L; Haites NE; McLeod HL Ann Saudi Med; 2004; 24(1):21-6. PubMed ID: 15310009 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a web-based treatment decision aid for men with lower urinary tract symptoms due to benign prostatic hyperplasia. van der Wijden FC; de Angst IB; Lamers RED; Cuypers M; de Vries M; van Melick HHE; de Beij JS; Oerlemans DJAJ; van de Beek K; Kil PJM BJU Int; 2019 Jul; 124(1):124-133. PubMed ID: 30589205 [TBL] [Abstract][Full Text] [Related]
19. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride. Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700 [TBL] [Abstract][Full Text] [Related]
20. Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. Morton A; Williams M; Perera M; Teloken PE; Donato P; Ranasinghe S; Chung E; Bolton D; Yaxley J; Roberts MJ BJU Int; 2020 Sep; 126 Suppl 1():18-26. PubMed ID: 32558340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]